ECSP13013016A - Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf - Google Patents

Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf

Info

Publication number
ECSP13013016A
ECSP13013016A ECSP13013016A ECSP13013016A EC SP13013016 A ECSP13013016 A EC SP13013016A EC SP13013016 A ECSP13013016 A EC SP13013016A EC SP13013016 A ECSP13013016 A EC SP13013016A
Authority
EC
Ecuador
Prior art keywords
piridin
ona
imidazol
inhibitors
derivatives
Prior art date
Application number
Other languages
English (en)
Inventor
Olaf Ritzeler
Gilbert Lassalle
Olivier Duclos
Valèrie Martin
Alain Braun
Franz Lorge
Aurélie Strub
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44247865&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP13013016A publication Critical patent/ECSP13013016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a los compuestos de la fórmula general (I)Procedimiento de preparación y uso terapéutico.
ECSP13013016 2011-05-20 2013-11-08 Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf ECSP13013016A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11305624A EP2524915A1 (en) 2011-05-20 2011-05-20 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
ECSP13013016A true ECSP13013016A (es) 2013-12-31

Family

ID=44247865

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013016 ECSP13013016A (es) 2011-05-20 2013-11-08 Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf

Country Status (35)

Country Link
US (2) US9126972B2 (es)
EP (2) EP2524915A1 (es)
JP (1) JP5937201B2 (es)
KR (1) KR102005121B1 (es)
CN (1) CN103687852B (es)
AR (1) AR086451A1 (es)
AU (1) AU2012261077B2 (es)
BR (1) BR112013029820B1 (es)
CA (1) CA2833192C (es)
CL (1) CL2013003091A1 (es)
CO (1) CO6811857A2 (es)
CR (1) CR20130541A (es)
CY (1) CY1116720T1 (es)
DK (1) DK2709996T3 (es)
DO (1) DOP2013000241A (es)
EA (1) EA023580B1 (es)
EC (1) ECSP13013016A (es)
ES (1) ES2548266T3 (es)
GT (1) GT201300250A (es)
HR (1) HRP20150974T1 (es)
HU (1) HUE025111T2 (es)
IL (1) IL229210A0 (es)
MA (1) MA35196B1 (es)
MX (1) MX348842B (es)
NI (1) NI201300125A (es)
PE (1) PE20141527A1 (es)
PL (1) PL2709996T3 (es)
PT (1) PT2709996E (es)
SG (1) SG194204A1 (es)
SI (1) SI2709996T1 (es)
TN (1) TN2013000420A1 (es)
TW (1) TWI532740B (es)
UA (1) UA109942C2 (es)
UY (1) UY34082A (es)
WO (1) WO2012159959A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
KR102068860B1 (ko) * 2012-07-17 2020-01-21 사노피 Vegfr-3 저해제의 간세포암 치료를 위한 용도
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
SG11202006903WA (en) * 2018-01-31 2020-08-28 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
CN1191252C (zh) * 2003-08-11 2005-03-02 中国药科大学 3－位取代的喹诺酮衍生物及其在药学上的应用
WO2005046589A2 (en) * 2003-11-07 2005-05-26 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
KR100744826B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 이미다졸기가 치환된 퀴놀리논 유도체
CA2682231A1 (en) 2007-03-28 2008-10-09 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2009053799A1 (en) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010073078A2 (en) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
KR102068860B1 (ko) * 2012-07-17 2020-01-21 사노피 Vegfr-3 저해제의 간세포암 치료를 위한 용도

Also Published As

Publication number Publication date
CR20130541A (es) 2013-12-09
NI201300125A (es) 2014-02-20
IL229210A0 (en) 2014-01-30
US9126972B2 (en) 2015-09-08
BR112013029820A2 (pt) 2016-12-06
US20150328205A1 (en) 2015-11-19
MX2013013572A (es) 2014-01-16
AU2012261077B2 (en) 2016-05-05
EA201391744A1 (ru) 2014-03-31
MA35196B1 (fr) 2014-06-02
SI2709996T1 (sl) 2015-10-30
CO6811857A2 (es) 2013-12-16
JP2014513707A (ja) 2014-06-05
CY1116720T1 (el) 2017-03-15
UY34082A (es) 2013-01-03
HUE025111T2 (en) 2016-02-29
CA2833192C (en) 2019-10-22
US9675606B2 (en) 2017-06-13
HRP20150974T1 (en) 2015-10-09
EP2524915A1 (en) 2012-11-21
EP2709996A1 (en) 2014-03-26
EP2709996B1 (en) 2015-06-24
GT201300250A (es) 2015-03-05
TW201300386A (zh) 2013-01-01
KR102005121B1 (ko) 2019-07-29
NZ617931A (en) 2015-05-29
EA023580B1 (ru) 2016-06-30
DK2709996T3 (en) 2015-09-28
CN103687852A (zh) 2014-03-26
CA2833192A1 (en) 2012-11-29
AR086451A1 (es) 2013-12-11
SG194204A1 (en) 2013-12-30
MX348842B (es) 2017-06-30
JP5937201B2 (ja) 2016-06-22
WO2012159959A1 (en) 2012-11-29
PT2709996E (pt) 2015-10-16
PE20141527A1 (es) 2014-11-08
CN103687852B (zh) 2016-08-17
AU2012261077A1 (en) 2013-12-12
KR20140025465A (ko) 2014-03-04
TN2013000420A1 (en) 2015-03-30
TWI532740B (zh) 2016-05-11
PL2709996T3 (pl) 2015-12-31
CL2013003091A1 (es) 2014-04-04
DOP2013000241A (es) 2013-12-31
US20140094488A1 (en) 2014-04-03
UA109942C2 (ru) 2015-10-26
BR112013029820B1 (pt) 2020-02-04
ES2548266T3 (es) 2015-10-15

Similar Documents

Publication Publication Date Title
ECSP15022555A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
ECSP13013016A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
CR20130625A (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CR20150144A (es) Derivados de etinilo como moduladores del receptor de actividad mglur5
CO6761304A2 (es) Nuevos compuestos de bezodioxol-piperazina
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
CY1118852T1 (el) Παραγωγα πυριμιδοοξαζοσινης ως αναστολεις της mtor
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
CO6900142A2 (es) Derivados de etinilo como moduladores del receptor metatrópico de glutamato